Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 507-510

  Tardy Poncet, B ^a   Tardy, B ^b   Laporte, S ^b   Mismetti, P ^b   Amiral, J ^c   Piot, M ^a   Reynaud, J ^a   Campos, L ^a   Decousus, H ^b  

^a Hôpital Nord   (France)

^b SERVICE DE NEUROLOGIE   (France)

^c SYSMEX CORPORATION   (Japan)

Author keywords

Tissue factor pathway inhibitor; Venous thrombosis

Indexed keywords

LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CASE CONTROL STUDY; DRUG EFFECT; DRUG RESISTANCE; FAMILY HEALTH; FEMALE; HUMAN; MALE; MIDDLE AGED; RISK; RISK FACTOR; VEIN THROMBOSIS;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; DRUG RESISTANCE; FAMILY HEALTH; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0642372609     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00086.x     Document Type: Article

References (20)

1. Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-70.
2. Arnaud E, Moatti D, Emmerich J, Aiach M, de Prost D. No link between the TFPI V264M mutation and venous thromboembolic disease. Thromb Haemost 1999; 82: 159-60.
3. Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, Kawasaki T, Kato H. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80: 345-6.
4. Kleesiek K, Schmidt M, Gotting C, Schwenz B, Lange S, Muller-Berghaus G, Brinkmann T, Prohaska W. The 536C!T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
5. Gonzalez-Conejero R, Lozano ML, Corral J, Martinez C, Vicente V. The TFPI 536C!T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost 2000; 83: 787-8.
6. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
7. Ariens RAS, Alberio G, Moia M, Mannucci PM. Low levels of heparinreleasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 203-7.
8. Tardy-Poncet B, Tardy B, Mismetti P, Laporte-Simitsidis S, Guyotat D, Decousus H. Heparin releasable tissue factor pathway inhibitor in young patients with venous thrombosis. Thromb Haemost Suppl 1999, 2372.
9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C. prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
10. Sandset P, Abildgaard U, Larsen M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
11. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post heparin plasma and in plasma from cancer patients. Blood Coag Fibrinol 1991; 2: 713-21.
12. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ, Simari RD. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor. a novel link between lipoproteins and thrombosis. Blood 2001; 98: 980-2987.
13. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
14. Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport S. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/ tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
15. Baugh RJ, Broze GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
16. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
17. Chang YJ, Hamaguchi N, Chang SC, Ruf W, Lin SW. Engineered recombinant factor VII, Q217 variants with altered inhibitor specificities. Biochemistry 1999; 38: 10940-8.
18. Neuenschwander PF, Morrissey JH. Alteration of the substrate and inhibitor specificities of blood coagulation factor VIIa: importance of amino acid residue K 192. Biochemistry 1995; 34: 8701-7.
19. Iakhiaev A, Ruf W, Mohan Rao LV. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Thromb Haemost 2001; 85: 458-63.
20. Girard TJ, MacPhail LA, Likert KM, Novotny WF, Miletich JP, Broze GJ. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990; 248: 1421-4.